P2RY12 and coronary artery disorder: One pivotal trial by Naveen L Pereira et al evaluated the impact of genotype-guided oral P2Y12 inhibitor therapy on ischemic outcomes in patients with CAD who are carriers of CYP2C19 LOF alleles.[12] This study demonstrated that genotype-guided therapy reduced the incidence of ischemic events compared to conventional therapy, highlighting the potential clinical benefits of tailored antiplatelet treatment strategies based on genetic profiles.